0.00
price down icon100.00%   -1.82
 
loading
Innate Pharma Adr stock is traded at $0.00, with a volume of 0. It is down -100.00% in the last 24 hours and down -100.00% over the past month. Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
See More
Previous Close:
$1.82
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$182.47M
Revenue:
$47.04M
Net Income/Loss:
$-63.98M
P/E Ratio:
0.00
EPS:
-0.8064
Net Cash Flow:
$-34.39M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
Value
$0.00
$0.00
1-Week Range:
Value
$0.00
$1.92
52-Week Range:
Value
$0.00
$3.5107

Innate Pharma Adr Stock (IPHA) Company Profile

Name
Name
Innate Pharma Adr
Name
Phone
-
Name
Address
-
Name
Employee
177
Name
Twitter
@InnatePharma
Name
Next Earnings Date
2024-09-12
Name
Latest SEC Filings
Name
IPHA's Discussions on Twitter

Compare IPHA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IPHA
Innate Pharma Adr
0.00 182.47M 47.04M -63.98M -34.39M -0.8064
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.62 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.91 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.49 28.51B 3.81B -644.79M -669.77M -6.24

Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-03-21 Upgrade SVB Leerink Mkt Perform → Outperform
Dec-15-20 Downgrade SVB Leerink Outperform → Mkt Perform
Nov-24-20 Initiated Goldman Neutral

Innate Pharma Adr Stock (IPHA) Latest News

pulisher
May 28, 2025

Why Kingsoft Cloud Holdings Stock Plummeted by Nearly 8% Today - The Globe and Mail

May 28, 2025
pulisher
May 13, 2025

Earnings call transcript: Innate Pharma Q1 2025 earnings reveal strategic focus By Investing.com - Investing.com South Africa

May 13, 2025
pulisher
May 13, 2025

Earnings call transcript: Innate Pharma Q1 2025 earnings reveal strategic focus - Investing.com India

May 13, 2025
pulisher
May 13, 2025

Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook - Investing.com

May 13, 2025
pulisher
May 13, 2025

Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook By Investing.com - Investing.com South Africa

May 13, 2025
pulisher
Apr 30, 2025

Innate Pharma reports promising preclinical results for cancer drug IPH4502 By Investing.com - Investing.com India

Apr 30, 2025
pulisher
Apr 29, 2025

Innate Pharma stock surges on promising preclinical data By Investing.com - Investing.com South Africa

Apr 29, 2025
pulisher
Apr 29, 2025

Innate Pharma reports promising preclinical results for cancer drug IPH4502 - Investing.com

Apr 29, 2025
pulisher
Apr 24, 2025

H.C. Wainwright maintains $11 target on Innate Pharma stock By Investing.com - Investing.com South Africa

Apr 24, 2025
pulisher
Apr 24, 2025

H.C. Wainwright maintains $11 target on Innate Pharma stock - Investing.com

Apr 24, 2025
pulisher
Mar 28, 2025

H.C. Wainwright maintains Buy rating on Innate Pharma stock By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

H.C. Wainwright maintains Buy rating on Innate Pharma stock - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Innate Pharma Reports 2024 Financial Results and Clinical Progress - TipRanks

Mar 28, 2025
pulisher
Mar 27, 2025

Earnings call transcript: Innate Pharma Q4 2024 sees strategic advances By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Earnings call transcript: Innate Pharma Q4 2024 sees strategic advances - Investing.com

Mar 27, 2025
pulisher
Jan 17, 2025

Innate Pharma shares retain Buy rating on long-term strategy - Investing.com

Jan 17, 2025
pulisher
Dec 23, 2024

AZN Stock Price and Chart — LSE:AZN - TradingView

Dec 23, 2024
pulisher
Aug 06, 2024

Contrast Security Introduces Application Detection and Response (ADR) to Identify and Block Attacks and Zero Days on Applications in Production - Business Wire

Aug 06, 2024
pulisher
Jun 10, 2024

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace

Jun 10, 2024
pulisher
Mar 31, 2024

symbol__ Stock Quote Price and Forecast - CNN

Mar 31, 2024
pulisher
Jan 04, 2024

Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study - Zacks Investment Research

Jan 04, 2024
pulisher
Dec 12, 2022

Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286 - Business Wire

Dec 12, 2022
pulisher
Apr 29, 2022

Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities.com

Apr 29, 2022
pulisher
Dec 16, 2021

ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire

Dec 16, 2021
pulisher
Nov 01, 2019

Innate Pharma (IPHA) Stock Price, News & Analysis - MarketBeat

Nov 01, 2019

Innate Pharma Adr Stock (IPHA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
Cap:     |  Volume (24h):